Patent & IP news for June 16, 2013

Interim injunctions pending an appeal: Court restates principles from patlit.blogspot.com

In Novartis AG v Hospira UK Ltd [2013] EWCA Civ 583, a decision of the Court of Appeal, England and Wales, of 22 May, the court, consisting of Lords Justices Lewison, Kitchin and Floyd), restated ...

Share via E–mail | Twitter | Facebook

What one hand gives, the other takes away? A deeper look at Myriad from ipkitten.blogspot.com

Catering for all tastes, this weblog has provided (i) the breaking news announcement by Jeremy that the US Supreme Court had given its ruling in Myriad Geetics and (ii) a mouth-watering hors d'oeuvres from ...

Share via E–mail | Twitter | Facebook

SHIELD Act Part 2 and Other Proposals to Combat Trolls from www.ipwatchdog.com

The latest incarnation of the SHIELD Act was introduced on February 27, 2013, and changes direction as if the first iteration were waived off in disgust before it could even lower its gears. SHIELD Act ...

Share via E–mail | Twitter | Facebook

CBS Sunday Morning on 16 June 2013 (Fathers Day) from ipbiz.blogspot.com

Lee Cowan.

The Sunday Morning cover story was by Lee Cowan on the lives of the astronaut wives.

Second, story on comedian Jim Gaffigan. Fatherhood.

Third, Mo Rocca on Debbie Reynolds. The good girl you ...

Share via E–mail | Twitter | Facebook

AMP v. Myriad: Getting Beyond the Hype and Hyperbole* from www.ipwatchdog.com

By holding that Myriad’s claimed cDNA was patent-eligible, Thomas’ opinion reaffirms the major holding in Diamond v. Chakrabarty that claimed subject matter which truly only the “hand of man” can make (not simply snipped ...

Share via E–mail | Twitter | Facebook

Costs and benefits of (some) US patents from ipfinance.blogspot.com


"The Costs and Bene fits of United States Patents" is the title of a paper by a four-man team consisting of John Turner, James Bessen, Peter Neuhäusler and Jonathan Williams. Labelled both as Boston Univ ...

Share via E–mail | Twitter | Facebook

Supreme Court Holds That Isolation of DNA Does Not Confer Patent Eligibility Under 35 U.S.C. § 101 from www.orangebookblog.com

Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. ____ (2013) by Christopher P. Singer "We merely hold that genes and the information they encode are not patent eligible under § 101 simply ...

Share via E–mail | Twitter | Facebook

Board reverses substitution benefit from allthingspros.blogspot.com

Takeaway: The Examiner relied on a substitution rationale in rejecting claims to a vertebral disc prosthesis. The rejection replaced circumferentially oriented radiopaque markers in the primary reference with radially oriented marker from the secondary reference ...

Share via E–mail | Twitter | Facebook

Conference & CLE Calendar from www.patentdocs.org

June 18, 2013 - Myriad: Implications of the U.S. Supreme Court Opinion (Intellectual Property Owners Association) - 2:00 to 3:00 pm (ET) June 25, 2013 - AIA Impact on Section 103 and Non-Obviousness: Navigating Timing ...

Share via E–mail | Twitter | Facebook

Court Report from www.patentdocs.org

By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Fresenius Kabi USA, LLC v. Watson Laboratories Inc. et al. 1:13-cv-01015; filed June 6, 2013 ...

Share via E–mail | Twitter | Facebook

Guest Post by Paul Cole: ASSOCIATION FOR MOLECULAR PATHOLOGY v MYRIAD GENETICS – an isolated decision? from www.patentlyo.com

Guest Commentary by Paul Cole,Professor of Intellectual Property Law, Bournemouth University, and European Patent Attorney, Lucas & Co, Warlingham, Surrey, UK. ASSOCIATION FOR MOLECULAR PATHOLOGY v MYRIAD GENETICS – an isolated decision? By Paul Cole[1 ...

Share via E–mail | Twitter | Facebook